An important example is imatinib, a kinase inhibitor originally approved for the treatment of patients with BCR-ABL-positive chronic myeloid leukemia, which is also a very effective inhibitor of KIT and thus showed increased efficacy in KIT-mutated GIST. This evidence concerns the gene KIT and gastrointestinal stromal tumor.